SRR8943035
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.400
- PEROXISOME+0.290
- APICAL_SURFACE+0.250
- PANCREAS_BETA_CELLS+0.230
- FATTY_ACID_METABOLISM+0.210
- XENOBIOTIC_METABOLISM+0.200
- MYOGENESIS+0.180
- BILE_ACID_METABOLISM+0.160
- OXIDATIVE_PHOSPHORYLATION+0.160
- ADIPOGENESIS+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.390
- ALLOGRAFT_REJECTION-0.360
- INTERFERON_GAMMA_RESPONSE-0.340
- TGF_BETA_SIGNALING-0.340
- IL2_STAT5_SIGNALING-0.310
- TNFA_SIGNALING_VIA_NFKB-0.270
- UV_RESPONSE_DN-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- HYPOXIA-0.250
- INFLAMMATORY_RESPONSE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.840 |
| 2 | 530f723a-ac5b-4e14-93b9-1d501b92fddd | — | — | 0.816 |
| 3 | TCGA-AC-A62V-01A-11R-A31O-07 | — | B | 0.809 |
| 4 | MNG662 | — | — | 0.782 |
| 5 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.779 |
| 6 | SRR8518303 | — | C | 0.778 |
| 7 | 63e18642-fcf3-460b-95de-de16428dea6d | — | — | 0.778 |
| 8 | TCGA-94-7943-01A-11R-2187-07 | — | cohortMD1 | 0.773 |
| 9 | ERR3262561 | — | — | 0.773 |
| 10 | TCGA-33-A5GW-01A-11R-A27Q-07 | — | cohortSQ2 | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |